VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | PEGASUS: APL-2 for PNH

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses a Phase III study (NCT03500549) evaluating the efficacy and safety of APL-2, a complement 3 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter